BIOMARKER:

EGFR amplification

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Glioblastoma

Non Small Cell Lung Cancer

Squamous Cell Carcinoma of Head and Neck

Esophageal Squamous Cell Carcinoma

Gastric Cancer

Lung Non-Small Cell Squamous Cancer

Colorectal Cancer

Glioma

Solid Tumor

Lung Adenocarcinoma

Triple Negative Breast Cancer

Urothelial Cancer

Esophageal Cancer

Mucosal Melanoma

Lung Cancer

Oral Cancer

Melanoma

afatinib

EGFR amplification|Non Small Cell Lung Cancer|afatinib

EGFR amplification|Squamous Cell Carcinoma of Head and Neck|afatinib

EGFR amplification|Esophageal Squamous Cell Carcinoma|afatinib

EGFR amplification|Lung Adenocarcinoma|afatinib

EGFR amplification|Urothelial Cancer|afatinib

EGFR amplification|Oral Cancer|afatinib

ABT-414

EGFR amplification|Glioblastoma|ABT-414

EGFR amplification|Glioma|ABT-414

cetuximab

EGFR amplification|Gastric Cancer|cetuximab

EGFR amplification|Colorectal Cancer|cetuximab

EGFR amplification|Triple Negative Breast Cancer|cetuximab

EGFR amplification|Oral Cancer|cetuximab

gefitinib

EGFR amplification|Non Small Cell Lung Cancer|gefitinib

EGFR amplification|Lung Cancer|gefitinib

EGFR amplification|Oral Cancer|gefitinib

erlotinib

EGFR amplification|Non Small Cell Lung Cancer|erlotinib

EGFR amplification|Glioblastoma|erlotinib

EGFR amplification|Oral Cancer|erlotinib

lapatinib

EGFR amplification|Glioblastoma|lapatinib

EGFR amplification|Oral Cancer|lapatinib

KD019

EGFR amplification|Glioblastoma|KD019

bevacizumab

EGFR amplification|Glioblastoma|bevacizumab

panitumumab

EGFR amplification|Colorectal Cancer|panitumumab

ABSK091

EGFR amplification|Solid Tumor|ABSK091

bevacizumab + erlotinib

EGFR amplification|Non Small Cell Lung Cancer|bevacizumab + erlotinib

bevacizumab + gefitinib

EGFR amplification|Non Small Cell Lung Cancer|bevacizumab + gefitinib

pembrolizumab + afatinib

EGFR amplification|Squamous Cell Carcinoma of Head and Neck|pembrolizumab + afatinib

KN046

EGFR amplification|Non Small Cell Lung Cancer|KN046

Z650

EGFR amplification|Esophageal Squamous Cell Carcinoma|Z650

BCA101

EGFR amplification|Lung Non-Small Cell Squamous Cancer|BCA101

cetuximab + HMBD-001

EGFR amplification|Lung Non-Small Cell Squamous Cancer|cetuximab + HMBD-001

pembrolizumab

EGFR amplification|Glioblastoma|pembrolizumab

EGFR amplification|Mucosal Melanoma|pembrolizumab

pembrolizumab + bevacizumab

EGFR amplification|Glioblastoma|pembrolizumab + bevacizumab

nivolumab

EGFR amplification|Glioblastoma|nivolumab

EGFR amplification|Mucosal Melanoma|nivolumab

BDTX-1535

EGFR amplification|Non Small Cell Lung Cancer|BDTX-1535

EGFR amplification|Glioblastoma|BDTX-1535

ABBV-221

EGFR amplification|Glioblastoma|ABBV-221

RG6330

EGFR amplification|Esophageal Squamous Cell Carcinoma|RG6330

nivolumab + bevacizumab

EGFR amplification|Glioblastoma|nivolumab + bevacizumab

nivolumab + ipilimumab

EGFR amplification|Mucosal Melanoma|nivolumab + ipilimumab

ipilimumab

EGFR amplification|Mucosal Melanoma|ipilimumab

osimertinib

EGFR amplification|Non Small Cell Lung Cancer|osimertinib

verteporfin

EGFR amplification|Glioblastoma|verteporfin

talazoparib

EGFR amplification|Glioma|talazoparib

icotinib

EGFR amplification|Lung Cancer|icotinib

AZD0530

EGFR amplification|Oral Cancer|AZD0530

Immunotherapy

EGFR amplification|Squamous Cell Carcinoma of Head and Neck|Immunotherapy

EGFR amplification|Melanoma|Immunotherapy

EGFR inhibitor

EGFR amplification|Gastric Cancer|EGFR inhibitor

EGFR amplification|Esophageal Cancer|EGFR inhibitor